These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19933982)

  • 1. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
    Dubbink HJ; Taal W; van Marion R; Kros JM; van Heuvel I; Bromberg JE; Zonnenberg BA; Zonnenberg CB; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Smitt PA; Dinjens WN; van den Bent MJ
    Neurology; 2009 Nov; 73(21):1792-5. PubMed ID: 19933982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
    Taal W; Dubbink HJ; Zonnenberg CB; Zonnenberg BA; Postma TJ; Gijtenbeek JM; Boogerd W; Groenendijk FH; Kros JM; Kouwenhoven MC; van Marion R; van Heuvel I; van der Holt B; Bromberg JE; Sillevis Smitt PA; Dinjens WN; van den Bent MJ;
    Neuro Oncol; 2011 Feb; 13(2):235-41. PubMed ID: 21177338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.
    Houillier C; Wang X; Kaloshi G; Mokhtari K; Guillevin R; Laffaire J; Paris S; Boisselier B; Idbaih A; Laigle-Donadey F; Hoang-Xuan K; Sanson M; Delattre JY
    Neurology; 2010 Oct; 75(17):1560-6. PubMed ID: 20975057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.
    Kizilbash SH; Giannini C; Voss JS; Decker PA; Jenkins RB; Hardie J; Laack NN; Parney IF; Uhm JH; Buckner JC
    J Neurooncol; 2014 Oct; 120(1):85-93. PubMed ID: 24993250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas.
    Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C
    J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
    Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
    J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
    Baumert BG; Hegi ME; van den Bent MJ; von Deimling A; Gorlia T; Hoang-Xuan K; Brandes AA; Kantor G; Taphoorn MJB; Hassel MB; Hartmann C; Ryan G; Capper D; Kros JM; Kurscheid S; Wick W; Enting R; Reni M; Thiessen B; Dhermain F; Bromberg JE; Feuvret L; Reijneveld JC; Chinot O; Gijtenbeek JMM; Rossiter JP; Dif N; Balana C; Bravo-Marques J; Clement PM; Marosi C; Tzuk-Shina T; Nordal RA; Rees J; Lacombe D; Mason WP; Stupp R
    Lancet Oncol; 2016 Nov; 17(11):1521-1532. PubMed ID: 27686946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
    SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
    Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
    Wick W; Platten M; Meisner C; Felsberg J; Tabatabai G; Simon M; Nikkhah G; Papsdorf K; Steinbach JP; Sabel M; Combs SE; Vesper J; Braun C; Meixensberger J; Ketter R; Mayer-Steinacker R; Reifenberger G; Weller M;
    Lancet Oncol; 2012 Jul; 13(7):707-15. PubMed ID: 22578793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimation of the occurrence rates of
    Cho U; Yang SH; Yoo C
    J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Temozolomide. A new option for high-grade astrocytomas.
    Schwenka J; Ignoffo RJ
    Cancer Pract; 2000; 8(6):311-3. PubMed ID: 11898150
    [No Abstract]   [Full Text] [Related]  

  • 13. IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.
    Stockhammer F; Misch M; Helms HJ; Lengler U; Prall F; von Deimling A; Hartmann C
    Seizure; 2012 Apr; 21(3):194-7. PubMed ID: 22217666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NICE verdict on Temozolomide: where next?
    Brada M
    Br J Cancer; 2002 Feb; 86(4):499-500. PubMed ID: 11870526
    [No Abstract]   [Full Text] [Related]  

  • 18. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
    Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
    PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3.
    Weller J; Katzendobler S; Blobner J; Thiele F; Becker H; Quach S; Egensperger R; Niyazi M; Suchorska B; Thon N; Weller M; Tonn JC
    J Neurooncol; 2022 Oct; 160(1):149-158. PubMed ID: 36112301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.
    Beiko J; Suki D; Hess KR; Fox BD; Cheung V; Cabral M; Shonka N; Gilbert MR; Sawaya R; Prabhu SS; Weinberg J; Lang FF; Aldape KD; Sulman EP; Rao G; McCutcheon IE; Cahill DP
    Neuro Oncol; 2014 Jan; 16(1):81-91. PubMed ID: 24305719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.